DARE Logo

COVID​

COVID-19 Flatten The Curve

The Permanente Medical Group COVID-19 Clinical Research Coordinating Team (CCRCT) supports evidence-based research in SARS-CoV-2 virus epidemiology including the diagnosis, treatment and prevention of COVID-19 and other clinical outcomes at Kaiser Permanente Northern California.


CCRCT Team Members


Gabriel J. Escobar, MD (co-chair)
TPMG Regional Director for Hospital Operations Research
Nicola P. Klein, MD, PhD (co-chair)
Director, Vaccine Study Center
Jacek Skarbinski, MD (co-chair)
Infectious Disease Physician (OAK) and Adjunct Investigator, DOR
Douglas A. Corley, MD, PhD
TPMG Regional Director for Delivery Science and Applied Research
Alan S. Go, MD
Director, KPNC Clinical Trials Program and Associate Director, Cardiovascular and Metabolic Research, DOR
Tracy A. Lieu, MD, MPH
Director, Division of Research
Vincent Liu, MD, MS
TPMG Regional Director for Hospital Advanced Analytics
Michael J. Silverberg, PhD, MPH
Senior Research Scientist, DOR

Clinical Trials (Active and those with completed enrollment)


  • A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5773) in Participants with Severe COVID-19 (Oakland, San Francisco, San Leandro, South San Francisco, Santa Clara, and San Jose Medical Centers) (closed to enrollment) Skarbinski, J

  • A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5774) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment (San Francisco, Oakland, San Leandro, South San Francisco, Santa Clara, and San Jose Medical Centers) (closed to enrollment) Skarbinski, J

  • A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-9012) Treatment of COVID-19 in an Outpatient Setting (closed to enrollment) Skarbinski, J

  • A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection (XPORT-CoV-1001) (Oakland, San Francisco, and Sacramento Medical Centers) (closed to enrollment) Skarbinski, J

  • Phase 1/2/3, Placebo-controlled, Randomized, Observer-blind, Dose-finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (closed to enrollment) Klein, N

  • COVID-19 Lattice Swab Evaluation Study (TPMG/DARE-Rapid Analytics Unit) (closed to enrollment)  Corley, D

  • KP NOURISH: Evaluation of the Clinical Utility of Medically-Tailored Meals in Adults with Chronic Conditions (closed to enrollment) Go, A
  • A Phase 3, Randomized, Observer-Blind Study to Evlauate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of the Vaccine Candidate BNT162b2 Against COVID-19 in Healthy Participants 12 Through 50 Years of Age (closed to enrollment) Klein, N
  • CISA COVID-19 Pediatric Study Kaiser (CDC/DHHS) (closed to enrollment) Klein, N 
  • A multicenter, randomized, placebo-controlled, pragmatic Phase 3 study investigating the efficacy and safety of rivaroxaban to reduce the risk of major venous and arterial thrombotic events, hospitalization and death in medically ill outpatients with acute, symptomatic COVID-19 infection (PREVENT HD) (open to enrollment) Go, A
  • A Phase 1, Open-Label Dose-Finding Study To Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of SARS-CoV-2 RNA Vaccine Candidate Against COVID-19 In Healthy Children <12 Years of Age (Closed to enrollment) N. Klein
  • A Phase 3 Master Protocol to Evaluate Additional Dose(s) of BNT162B2 in Health Individuals Previously Vaccinated with BNT162B2. N Klein (closed to enrollment)

Active Clinical Studies


  • Characteristics and Clinical Trajectory of COVID-19 Patients Admitted from the Emergency Department (The CREST Network/ DARE-Rapid Analytics Unit) Reed, M. 

  • Risk of COVID-19 pandemic on immunosuppressed populations
    (DARE-Rapid Analytics Unit) Velayos. F. 

  • Decision support and risk prediction for clinicians coping with the COVID-19 pandemic Escobar, G

  • Evaluating the impact of cancer on COVID-19 diagnoses and outcomes
    (DARE-Rapid Analytics Unit) Harzstark, A

  • KPNC mental health services utilization, outcomes, and associated patient characteristics during the COVID-19 pandemic (TPMG/DARE) Erickson-Ridout, K

  • How COVID Changed Our Practice: Telehealth in TPMG Surgical Cancer Care
    (TPMG/DARE-Rapid Analytics Unit) Kuehner, G

  • COVID surveillance (CDC Vaccine Safety Datalink population-based surveillance) (Division of Research) Klein, N

  • The impact of the use of anticoagulants and antiplatelets on the risk of hospitalization and mortality in patients with COVID-19.
    (TPMG/DARE-Rapid Analytics Unit) Pai, A

  • KP Research Bank member survey on  effects of  COVID-19 epidemic (Kaiser Permanente/Division of Research) McGlynn, E

  • A Multi-center, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults with Severe COVID-19 (Division of Research) Go, A

  • COVID-19-Associated Hospitalization Surveillance in Children and Adults (Division of Research) Skarbinski, J

  • Advancing Understanding of the Impact of Smoking Status on COVID (Division of Research) Young-Wolff, K

  • The impact of COVID-19 pandemic on health status and healthcare utilization among adults with autism spectrum disorders (WITH Foundation (formerly Special Hope Foundation)) Croen, L

  • Innovative Methods to Inform Estimates of Vaccine Effectiveness Using Information on the Epidemiology and Incidence of Influenza and Other Acute Respiratory Illnesses (Division of Research) Klein, N

  • Perinatal COVID-19 Infection National Registry (Med Center Based) Fischer, A

  • Effectiveness and safety of treatments for hospitalized patients with COVID-19 (DOR/Garfield Fund) Liu, V

  • Acute Emergency Care and Outcomes for Stroke, Myocardial Infarction, and Surgery During the COVID-19 Pandemic: Implications for Care Delivery During COVID-19 Recovery Phase and Future Surges (TPMG/DARE, DOR, Garfield Fund) Nguyen-Huynh , M  

  • Epidemiologic Analysis of Chilblains Eruptions at the time of COVID-19 (DARE-Rapid Analytics Unit) McCleskey, P

  • Incidence of outpatient thromboembolism in patients with SARS-CoV-2 infections (DARE-Rapid Analytics Unit) Roubinian, N

  • The Impact of California Shelter-In-Place on Incidence of Gynecologic Emergencies in a Community-Based Population (DARE-Rapid Analytics Unit) Zaritsky, E

  • Examining the "Hidden Epidemic": Consequences of COVID Social Distancing and Health Care System Responses among Patients with Complex Medical and Social Needs (Garfield Memorial Fund) Grant, R

  • COVID-19 pandemic: Impact on colorectal cancer screening and surveillance (Garfield Memorial Fund) Levin, T

  • Identifying Pre-Sepsis Opportunities for Early, Targeted Intervention - COVID19 (PreSepsis-COVID19) (National Institute of General Medical Sciences/NIH/DHHS) Liu, V

  • Comparison of Cross-Sex Hormone Therapies in Relation to Risks of Vascular Events: Characteristics of the COVID-19 Epidemic in Transgender Populations (PCORI) Silverberg, M

  • Utilizing real world data to describe clinical and safety outcomes among hospitalized COVID-19 patients, and to create a comparator arm for a randomized controlled trial evaluating the efficacy and safety of actemra for COVID-19 patients (Genentech) Skarbinski, J

  • Maternal Marijuana Use During Pregnancy, Marijuana Legalization, and Adverse Obstetrical and Neonatal Outcomes: A 12-year Cohort Study (COVID-19 Revision) (National Institute on Drug Abuse/NIH/DHHS) Young-Wolff, K

  • NA-ACCORD Corona Infectious Virus Epidemiology Team (CIVETs) (National Institute of Allergy and Infectious Diseases/NIH/DHHS) Silverberg, M

  • COVID-19 Population Based evaluation of COVID-19 cases (CDC/DHHS) Klein, N

  • Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19 Waldron, P

  • Optimizing quality and safety in the era of COVID-19: Virtual care first utilization and outcomes for potentially emergent conditions among KPNC members (Garfield Memorial Fund) Kene, M

  • Rapid Cycle Analysis of COVID-19 vaccine(s) (CDC) Klein, N

  • Assessing the impact of changes in health care utilization during the COVID-19 pandemic on background rate trends and use of telemedicine encounters for vaccine adverse events of special interest.  (CDC) Klein, N

  • Vaccine Enhanced COVID-19 Disease monitoring (CDC) Klein, N

  • SARS-COV-2 vaccine safety evaluation in pregnant women and their infants (CDC) Klein, N

  • COVID-19 Pregnancy and Fetal Death (CDC) Klein, N

  • Assess influenza and COVID-19 vaccination coverage among pregnant women using automated data in VSD. (CDC) Klein, N

  • COVID-19 Infrastructure and Activities Vaccine Safety Datalink Project, VSD COVID-19 Infrastructure and Participating Activities (Centers for Disease Control and Prevention) Klein, N
  • The Epidemiology of SARS-CoV-2 in Pregnancy and Infancy (ESPI) Network:ESPI-Electronic Cohort (CDC) Li, De-Kun
  • COVID-19-Related Enhancements to "Evaluation of complex interventions on
    drug (re)fill behavior using electronic healthcare data" (Administrative
    Supplement) (PCORI) Neugebauer, R
  • Tools for Outpatient and Population Management of SARS COV-2 Infection (TOPS2) (TPMG Delivery Science Projects Program) Escobar, G
  • Convalescent COVID-19 Plasma Expanded Access Program (Kaiser Foundation Hospitals) Go, A

  • COVID-19 and Venous Thromboembolism Risk (Administrative Supplement)(Patient-Centered Outcomes Research Institute (PCORI)) Go, A
  • Innovative Methods to Inform Estimates of Vaccine Effectiveness
    Using Information on the Epidemiology and Incidence of Influenza and Other
    Acute Respiratory Illnesses (CDC) Klein, N
  • SARS-CoV-2 Serological Antibody Testing for Disease Surveillance and
    Clinical Use (NIH) Skarbinski, J

  • Descriptive Analysis of COPD patients with COVID-19 (Boehringer Ingelheim
    Pharmaceuticals, Inc.) Myers, L

  • Smoking and COVID-19 onset and severity in a US integrated healthcare
    delivery system (Tobacco-Related Disease Research Program) Piazza, K
  • Optimizing quality and safety in the era of COVID-19: Virtual care first
    utilization and outcomes for potentially emergent conditions among KPNC
    members (Garfield Memorial Fund) Mamata, K
  • COVID-19 Pandemic: Impact on Colorectal Cancer Screening and
    Adenoma Surveillance Outcomes (PICASO) (Garfield Memorial Fund) Levin, TR
  • COVID-19 related changes in health care delivery and health outcomes among pregnant women and their newborns (The Permanente Medical Group) Ferrara, A

  • Cross-Cohort Collaboration on COVID-19 Research (4CR) (National Heart, Lung, and Blood Institute) Sydney, S

  • Smoking and COVID-19 Onset and Severity in a US Integrated Health Care Delivery System (Tobacco-Related Disease Research Program) Young-Wolf, K

  • Monitoring Shared Variation in Genomes of SARS-CoV-2 Among Persons With COVID-19 With and Without Vaccination in Northern California (The Rockefeller Foundation) Skarbinski, J
  • Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) in Adult KPNC Members (TPMG Delivery Science Grants Program) Reed, M and Ballard, D